Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
This study has been completed.
Study NCT00035061 Information provided by Eli Lilly and Company
First Received: May 2, 2002 Last Updated: July 18, 2006
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Urologic Neoplasms
Metastases, Neoplasm
Additional conditions recognized in this trial
Carcinoma, Transitional Cell
Neoplasm Metastasis
Neoplasms
More general conditions related to this trial
Carcinoma
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplastic Processes
Pathologic Processes
Urogenital Neoplasms
Interventions listed in this trial
pemetrexed
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Eli Lilly and Company
Back to top of Main Content
